- Home
- HEI vs TAK Comparison
HEI vs TAK Comparison
Compare HEI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEI
- TAK
- Stock Information
- Founded
- HEI 1957
- TAK 1781
- Country
- HEI United States
- TAK Japan
- Employees
- HEI N/A
- TAK N/A
- Industry
- HEI Aerospace
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- HEI Industrials
- TAK Health Care
- Exchange
- HEI Nasdaq
- TAK Nasdaq
- Market Cap
- HEI 42.8B
- TAK 47.9B
- IPO Year
- HEI N/A
- TAK N/A
- Fundamental
- Price
- HEI $312.18
- TAK $14.99
- Analyst Decision
- HEI Buy
- TAK
- Analyst Count
- HEI 12
- TAK 0
- Target Price
- HEI $339.45
- TAK N/A
- AVG Volume (30 Days)
- HEI 508.1K
- TAK 3.4M
- Earning Date
- HEI 08-25-2025
- TAK 10-30-2025
- Dividend Yield
- HEI 0.08%
- TAK 3.62%
- EPS Growth
- HEI 34.01
- TAK N/A
- EPS
- HEI 4.57
- TAK 0.59
- Revenue
- HEI $4,289,298,000.00
- TAK $31,053,301,865.00
- Revenue This Year
- HEI $14.68
- TAK $0.40
- Revenue Next Year
- HEI $8.30
- TAK $0.83
- P/E Ratio
- HEI $68.28
- TAK $49.52
- Revenue Growth
- HEI 13.46
- TAK 1.52
- 52 Week Low
- HEI $216.68
- TAK $12.80
- 52 Week High
- HEI $338.92
- TAK $15.56
- Technical
- Relative Strength Index (RSI)
- HEI 48.20
- TAK 52.52
- Support Level
- HEI $304.39
- TAK $14.78
- Resistance Level
- HEI $336.44
- TAK $15.00
- Average True Range (ATR)
- HEI 7.35
- TAK 0.12
- MACD
- HEI 0.59
- TAK 0.00
- Stochastic Oscillator
- HEI 27.41
- TAK 39.60
About HEI Heico Corporation
Heico is an aerospace and defense supplier that focuses on creating replacement parts for commercial aircraft and components for defense products. In commercial aerospace, Heico is the largest independent producer of replacement aircraft parts. In the defense market, the company produces niche subcomponents used in targeting technology as well as simulation equipment, among other categories. It operates as two segments: the flight support group,or FSG, and the electronic technologies group, or ETG, both of which supply the aerospace and defense sectors to different degrees. The company is persistently acquisitive, focusing on companies in similar or adjacent markets that offer strong cash flow and profitable growth potential.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.